Surrogate markers for targeted therapy-based treatment activity and efficacy

Area of Science:

• Oncology
• Translational Medicine
• Biomarker Discovery

Background:

• Personalized medicine relies on predictive biomarkers to guide targeted therapy selection.
• Drug development often occurs in advanced disease stages, posing challenges for tumor sample acquisition.
• The neoadjuvant setting presents an opportunity to collect serial tumor samples and evaluate treatment effects.

Purpose of the Study:

• To highlight the potential of neoadjuvant studies for predictive biomarker development.
• To emphasize the utility of pathological complete response as an endpoint.
• To discuss the role of window-of-opportunity studies in biomarker validation.

Main Methods:

• Utilizing tumor samples collected at diagnosis and post-treatment surgery.
• Leveraging pathological complete response as a surrogate endpoint.
• Employing window-of-opportunity studies to assess drug effects by comparing pre- and post-treatment biopsies.

Main Results:

• Neoadjuvant studies facilitate the collection of critical tumor specimens.
• Pathological complete response is a reliable indicator of long-term survival.
• Window-of-opportunity studies enable direct assessment of drug impact.

Conclusions:

• Neoadjuvant and window-of-opportunity studies are essential for developing and validating predictive biomarkers.
• The neoadjuvant approach overcomes limitations in sample collection for biomarker discovery.
• Advancements in neoadjuvant investigations are expected to yield clinically useful predictive markers for targeted therapies.